ArticleOpen biology2020

Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH.

Stephanie J Crowley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.